Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
- Rodabe N. Amaria
- Sangeetha M. Reddy
- Jennifer A. Wargo
